anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To investigate the potential role of Tongxinluo (TXL) in attenuating myocardial fibrosis after myocardial ischemia-reperfusion injury (MIRI) in mice.
METHODS: A MIRI mouse model was established by left anterior descending coronary artery ligation for 45 min. According to a random number table, 66 mice were randomly divided into 6 groups (n=11 per group): the sham group, the model group, the LY-294002 group, the TXL group, the TXL+LY-294002 group and the benazepril (BNPL) group. The day after modeling, TXL and BNPL were administered by gavage. Intraperitoneal injection of LY-294002 was performed twice a week for 4 consecutive weeks. Echocardiography was used to measure cardiac function in mice. Masson staining was used to evaluate the degree of myocardial fibrosis in mice. Qualitative and quantitative analysis of endothelial mesenchymal transition (EndMT) after MIRI was performed by immunohistochemistry, immunofluorescence staining and flow cytometry, respectively. The protein expressions of platelet endothelial cell adhesion molecule-1 (CD31), α-smoth muscle actin (α-SMA), phosphatidylinositol-3-kinase (PI3K) and phospho protein kinase B (p-AKT) were assessed using Western blot.
RESULTS: TXL improved cardiac function in MIRI mice, reduced the degree of myocardial fibrosis, increased the expression of CD31 and inhibited the expression of α-SMA, thus inhibited the occurrence of EndMT (P<0.05 or P<0.01). TXL significantly increased the protein expressions of PI3K and p-AKT (P<0.05 or P<0.01). There was no significant difference between TXL and BNPL group (P>0.05). In addition, the use of the PI3K/AKT pathway-specific inhibitor LY-294002 to block this pathway and combination with TXL intervention, eliminated the protective effect of TXL, further supporting the protective effect of TXL.
CONCLUSION: TXL activated the PI3K/AKT signaling pathway to inhibit EndMT and attenuated myocardial fibrosis after MIRI in mice.
A composition is herein provided comprising a broad spectrum protein of microbial origin as active anti-HIV/AIDS agent. Either the protein is secreted by or surface associated in microorganisms including but not limiting to bacteria, both pathogenic and non-pathogenic. The proteins used are 10 isolated from bacteria Mycobacterium spp. specifically from Mycobacterium tuberculosis or M bovis BCG. Further, the protein could be substituted by various truncated derivatives thereof, peptides derived frorri such proteins, synthetically prepared peptides, and proteins or peptides modified by PEGylation, acetylation, and phosphorylation. The protein includes purified proteins and peptides having 15 amino acid sequence of SEQ ID No. 1and2 respectively.
Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
The present study investigated the role of early visual experience in the development of postural control (balance) and locomotion (gait). In a cross-sectional design, balance and gait were assessed in 59 participants (ages 7-43 years) with a history of (a) transient congenital blindness, (b) transient late-onset blindness, (c) permanent congenitally blindness, or (d) permanent late-onset blindness, as well as in normally sighted controls. Cataract-reversal participants who experienced a transient phase of blindness and gained sight through cataract removal surgery showed worse balance performance compared with sighted controls even when tested with eyes closed. Individuals with reversed congenital cataracts performed worse than individuals with reversed developmental (late emerging) cataracts. Balance performance in congenitally cataract-reversal participants when tested with eyes closed was not significantly different from that in permanently blind participants. In contrast, their gait parameters did not differ significantly from those of sighted controls. The present findings highlight both the need for visual calibration of proprioceptive and vestibular systems and the crossmodal adaptability of locomotor functions.
A Vitamin K animal feed premix comprises a menadione bisulphite adduct, a solid carrier and one or more acidic materials capable of inhibiting decomposition of the menadione bisulphite adduct in the premix, the carrier being a material which would normally promote decomposition of the menadione bisulphite adduct in the absence of the acidic material(s) and the acidic material(s) being present in sufficient proportions to inhibit such decomposition. The bisulphite adduct is preferably menadione sodium bisulphite, though other alkali metal, alkaline earth metal, ammonium or amine bisulphite salts may be used.  Carriers mentioned are calcite (preferred), soy bean meal (preferred), maize meal, corn cob meal, milo, soy bean oil meal, alfalfa meal, dried whey, wheat shorts, distillers' dried solubles, salt, meat scraps, butyl fermentation solubles, feather meal, poultry by-product meal, wheat middlings, dextrose, lactose meal, dried kelp, linseed oil meal, oatmeal, dried yeast and wheat bran.  Acidic materials mentioned are monocalcium phosphate; calcium sulphate, nitrate, lactate, stearate and glucuronate; potassium pyrophosphate and pyrosulphate; hemi-sodium phosphate; sodium acid pyrophosphate; ferric pyrophosphate and orthophosphate; trialuminium phosphate; monomagnesium phosphate; ammonium, zinc, iron, aluminium and manganese salts of hydrochloric, nitric and sulphuric acids; dibasic ammonium phosphate; acetyl salicylic acid; terephthalic acid; choline chloride; niacin; 2-furoic acid; and other organic and inorganic salts and organic acids.  Examples disclose that monopotassium phosphate, mono-ammonium phosphate, sodium potassium tartrate and potassium sulphate are unsuitable.  The acidic material should generally be present in an amount sufficient to lower the pH of a water extract of the premix to a value between about 4 and 6,5. Preferred premixes contain at least 4 grams menadione sodium bisulphite per pound and 12 to 36 grams of monocalcium phosphate per pound or, alternatively, at least 12 grams of terephthalic acid per pound and some monocalcium phosphate.  Other feed ingredients may be added to the premix. In certain examples, the comparative effects of coating the menadione bisulphite adduct with vegetable gum is studied.
Cardiotoxicity has emerged as a serious outcome catalyzed by various therapeutic targets in the field of cancer treatment, which includes chemotherapy, radiation, and targeted therapies. The growing significance of cancer drug-induced cardiotoxicity (CDIC) and radiation-induced cardiotoxicity (CRIC) necessitates immediate attention. This article intricately unveils how cancer treatments cause cardiotoxicity, which is exacerbated by patient-specific risks. In particular, drugs like anthracyclines, alkylating agents, and tyrosine kinase inhibitors pose a risk, along with factors such as hypertension and diabetes. Mechanistic insights into oxidative stress and topoisomerase-II-B inhibition are crucial, while cardiac biomarkers show early damage. Timely intervention and prompt treatment, especially with specific agents like dexrazoxane and beta-blockers, are pivotal in the proactive management of CDIC.
The study included 30 patients diagnosed with chronic periodontitis. Three sites from three different quadrants were selected and assigned to three groups namely, SRP group - scaling and root planing, LASER group - scaling and root planing with application of 810 nm diode laser and ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
Chronic pain disorder may be associated with mental health disease. Many patients exhibit behavioral problems. Some of the patients may sexually or racially harass the pain clinic staff. Typically, healthcare providers do not report racial or sexual harassment perpetrated by patients.

This is a quantitative analysis of prospective electronic and clinic diary data. It evaluates many incidents of sexual and racial harassment of pain clinic staff; perpetrated by patients. It analyzes the incident causative factors, incident outcomes, system factors and lessons learned. The qualitative information of each incident is presented in a sensitive and careful format.
Intravenous or intramuscular administration of the recommended dose of 2 mg to 4 mg of Lorazepam Injection to adult patients is followed by dose-related effects of sedation (sleepiness or drowsiness), relief of preoperative anxiety, and lack of recall of events related to the day of surgery in the majority of patients. The clinical sedation (sleepiness or drowsiness) thus noted is such that the majority of patients are able to respond to simple instructions whether they give the appearance of being awake or asleep. The lack of recall is relative rather than absolute, as determined under conditions of careful patient questioning and testing, using props designed to enhance recall. The majority of patients under these reinforced conditions had difficulty recalling perioperative events or recognizing props from before surgery. The lack of recall and recognition was optimum within 2 hours following intramuscular administration and 15 to 20 minutes after intravenous injection.

The intended effects of the recommended adult dose of Lorazepam Injection usually last 6 to 8 hours. In rare instances, and where patients received greater than the recommended dose, excessive sleepiness and prolonged lack of recall were noted. As with other benzodiazepines, unsteadiness, enhanced sensitivity to CNS-depressant effects of ethyl alcohol and other drugs were noted in isolated and rare cases for greater than 24 hours.
The management and prognosis of patients with metastatic cutaneous melanoma have changed dramatically with the advent of immunotherapy, especially anti-PD-1 antibodies. These immune-checkpoint inhibitor block the programmend cell death receptor 1 (PD1). Currently, two anti-PD-1 antibodies, nivolumab and pembrolizumab are available. Recent data for pembrolizumab show that the overall survival rate at almost 3 years is 50% and the overall response rate is 42%. Despite these results so far never achieved, about 60% of patients do not respond to anti-PD-1 immunotherapy and, at present, no clinical, imaging or biological markers are predictive of the therapeutic response. The identification of such markers is essential in order to guide the clinician in the choice of optimal treatment.

The objective of this study is to assess whether FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET-CT could be an early predictive method of therapeutic response to anti-PD-1 immunotherapy in metastatic melanoma.

The anti-tumor immune response to anti-PD-1 is related to the activation of immune cells infiltrating the tumor, in particular CD8+ (cluster of differentiation 8) T cells whose phenotype is that of "exhausted T cells". This immune activation is such that it sometimes causes (about 10% of cases) a transient increase in the size and/or number of lesions. This phenomenon, has been called "pseudo-progression" and it cannot be interpreted routinely by RECIST1.1 criteria. The exact kinetics and timing of CD8+ T cell activation leading to response to treatment is still unknown. It is possible that this cellular activation has an early metabolic translation detectable by 18FDG PET-CT. The investigator's hypothesis is that early 18FDG PET-CT, ie after 2 cycles of anti-PD1 in metastatic patient melanoma, could be predictive of the therapeutic response. 20 patients will be enrolled and undergo three PET/CT scans: a baseline PET-CT (PET0) before the start of anti-PD1 treatment, an early PET-CT after 2 cycles of anti-PD1 (PET1) and a third PET-CT after 3 months of initiation of treatment. Treatment response on FDG PET will be assessed according to PERCIST criteria. Changes in FDG uptake will be correlated with blood results.
The invention provides medicine for pyrophlegm tuberculous scrofula goiter and tumors. The medicine is composed of, by weight, 2-20 geckoes, 17-170 parts of fewflower lysionotus herbs, 16-160 parts of red semiaquilegia, 16-160 parts of clematis roots, 15-150 parts of rhoeo discolor, 17-170 parts of radix tetrastigme, 18-180 parts of Chinese lobelia, 18-180 pars of lysimachia christinae hance, 23-230 parts of polygala fallax hemsl, a proper amount of centipede liquor, EM primary liquid used according needs and a proper amount of Carbomer. The geckoes and Chinese lobelia are screened and cleaned, and are ground into sauce, a proper amount of EM primary liquid is added to be evenly stirred, still standing is carried out for one day, the toxin of the geckoes is decomposed, and mixed medicine of the geckoes and Chinese lobelia is formed. A proper amount of Carbomer and a proper amount of EM primary liquid are evenly stirred to be gelatinated, and are neutralized into a neutral thick body. The rest of the medicine is screened and cleaned, and is smashed into powder, the mixed medicine of the geckoes and Chinese lobelia, a proper amount of centipede liquor and a proper number of neutral thick body are added to be bound and evenly stirred, and tablets are formed in a pressed mode. The medicine has the functions of clearing away heat and toxic materials, reducing phlegm, resolving hard lumps and relieving swelling and pain, and can treat the goiter and tumors, scrofula, mammary nodes and other diseases.
<P>PROBLEM TO BE SOLVED: To obtain a readily disintegrable granulated material suitable for massage and having disintegrating properties so as not to cause problems in safety, and to provide a cosmetic comprising the granulated material.  <P>SOLUTION: The granulated material of at least two kinds of powder for cosmetics is characterized in that any of the constituent powder has the melting point not lower than the service temperature and the melting point of at least one kind of the powder thereof is present in a stable temperature region of the other powder component. Thereby, the granulated material is prepared and included in the cosmetics. Powder, or the like, of high-melting wax, e.g. polyethylene powder, carnauba wax, candelilla wax or beeswax are preferably exemplified as the low-melting powder to be a binder. Silica gel, cellulose, or the like, can be exemplified as the other stable powder.  <P>COPYRIGHT: (C)2004,JPO
Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
Disrupted host-microbe interactions at the mucosal level are key to the pathophysiology of IBD. This study aimed to comprehensively examine crosstalk between mucosal gene expression and microbiota in patients with IBD. To study tissue-specific interactions, we perform transcriptomic (RNA-seq) and microbial (16S-rRNA-seq) profiling of 697 intestinal biopsies (645 derived from 335 patients with IBD and 52 from 16 non-IBD controls). Mucosal gene expression patterns in IBD are mainly determined by tissue location and inflammation, whereas the mucosal microbiota composition shows a high degree of individual specificity. Analysis of transcript-bacteria interactions identifies six distinct groups of inflammation-related pathways that are associated with intestinal microbiota (adjusted P < 0.05). An increased abundance of Bifidobacterium is associated with higher expression of genes involved in fatty acid metabolism, while Bacteroides correlates with increased metallothionein signaling. In patients with fibrostenosis, a transcriptional network dominated by immunoregulatory genes is associated with Lachnoclostridium bacteria in non-stenotic tissue (adjusted P < 0.05), while being absent in CD without fibrostenosis. In patients using TNF-α-antagonists, a transcriptional network dominated by fatty acid metabolism genes is linked to Ruminococcaceae (adjusted P < 0.05). Mucosal microbiota composition correlates with enrichment of intestinal epithelial cells, macrophages, and NK-cells. Overall, these data demonstrate the presence of context-specific mucosal host-microbe interactions in IBD, revealing significantly altered inflammation-associated gene-taxa modules, particularly in patients with fibrostenotic CD and patients using TNF-α-antagonists. This study provides compelling insights into host-microbe interactions that may guide microbiota-directed precision medicine and fuels the rationale for microbiota-targeted therapeutics as a strategy to alter disease course in IBD.
MDM2 has been established as a biomarker indicating poor prognosis for individuals undergoing immune checkpoint inhibitor (ICI) treatment for different malignancies by various pancancer studies. Specifically, patients who have MDM2 amplification are vulnerable to the development of hyperprogressive disease (HPD) following anticancer immunotherapy, resulting in marked deleterious effects on survival rates. The mechanism of MDM2 involves its role as an oncogene during the development of malignancy, and MDM2 can promote both metastasis and tumor cell proliferation, which indirectly leads to disease progression. Moreover, MDM2 is vitally involved in modifying the tumor immune microenvironment (TIME) as well as in influencing immune cells, eventually facilitating immune evasion and tolerance. Encouragingly, various MDM2 inhibitors have exhibited efficacy in relieving the TIME suppression caused by MDM2. These results demonstrate the prospects for breakthroughs in combination therapy using MDM2 inhibitors and anticancer immunotherapy.
FIELD: veterinary parasitology, veterinary science. SUBSTANCE: invention relates to prophylaxis and treatment of agriculture animals with parasitic sicknesses. Invention proposes an agent for prophylaxis and treatment of agriculture animals with parasitic sicknesses that is an ivermectin solution in the mixture with polyethylene glycol-400; 80% of ethyl alcohol and benzyl alcohol at the following ratio of components: ivermectin 0.8-1.2 g/100 ml; polyethylene glycol 45-60 vol.%; 80%-th ethyl alcohol 35-45 vol.% and benzyl alcohol 2-10 vol. %. The use of ivercent provides 100% of an acaricide, insecticide and nematocide efficiency in pigs, sheep and cattle with parasitosis. EFFECT: enhanced effectiveness of an agent. 7 tbl, 5 ex
Duvelisib with ibrutinib will be administered for the first six 28-day (± 7) cycles followed by duvelisib alone until disease progression or intolerance. Duvelisib is an orally administered at 15 mg twice a day (dose level 1) or 25 mg twice day (dose level 2). Subjects will continue the same dose of ibrutinib prior to study enrollment for the first six 28-day cycles. Ibrutinib is an orally administered and provided as 140 mg white opaque capsules or tablets in 4 strengths: 140 mg, 280 mg, 420 mg, and 560 mg.
Although mechanical ventilation is a life-saving intervention, it can lead to ventilator-induced lung injury (VILI). VILI is the damage caused by positive pressure ventilation that starts with the use of mechanical ventilators. There are many factors that cause VILI such as tidal volume, drive pressure, flow, respiratory rate, and PEEP. Mechanical power, which collects these different variables in a single parameter, offers us new possibilities in predicting VILI at the bedside. The mechanical power being above a certain threshold causes damage ranging from pulmonary parenchymal rupture to severe inflammation and edema. Also, higher mechanical power values are associated with higher mortality. The protective ventilation strategy in intensive care units is also applied in operating rooms (OR) to minimize the risk of postoperative pulmonary complications due to VILI. While the volume control mode was at the forefront in the old anesthesia devices used in the OR, today there are anesthesia devices with many modes and features, as in intensive care units. This causes confusion in the use of mechanical ventilators in the perioperative period. Therefore, in this study, the investigators compared the perioperative mechanical power values in prone and supine positions, and postoperative pulmonary complications of two ventilation modes (volume control-pressure control ventilation). Thus, the investigators aimed to find out which ventilation mode would be advantageous in the perioperative period.
BACKGROUND: Italy initiated elexacaftor/tezacaftor/ivacaftor (ETI) for people with cystic fibrosis (pwCF) in July 2021. It has led to dramatic improvements in lung function, BMI, sweat chloride, and respiratory symptoms. However, few data are available on side effects or effects on a broad range of outcomes.
RESEARCH QUESTION: How does ETI affect mental health, cognitive processing, neuropsychological side effects, GI symptoms, and health-related quality of life over time?
STUDY DESIGN AND METHODS: This was a prospective, "real-world" longitudinal study. Participants were recruited consecutively and evaluated at initiation (T0) and after 1 month, 3 months, and 6 months of starting treatment. Assessments included depression (nine-item Patient Health Questionnaire), anxiety (seven-item Generalized Anxiety Disorder), cognition (Symbol Digit Modalities Test), GI Symptom Tracker, and health-related quality of life (Cystic Fibrosis Questionnaire-Revised). Based on literature, an ad hoc questionnaire was developed to assess side effects: insomnia, headache, memory problems, "brain fog," and concentration problems. Following descriptive analyses, longitudinal data were analyzed by using mixed models for repeated measures, controlling for age and sex when appropriate.
RESULTS: Ninety-two consecutive pwCF (female/male, 46/46; mean age, 25.4 years) participated. FEV1 increased initially and then remained stable. BMI also increased significantly from T0 to 6 months (P < .01). Depression improved from T0 to 1 month (P < .001); however, no changes in anxiety were found. Cognitive processing improved from T0 to subsequent assessments. Positive changes were reported on the GI Symptom Tracker for stools and adherence challenges, although no changes were found for abdominal pain and digestion. Side effects occurred in 10% to 29%, with no reduction over time; insomnia increased significantly across time. Female participants reported more side effects than male participants (ie, insomnia, headache, concentration problems, brain fog).
INTERPRETATION: This prospective study evaluated the effects of ETI using multiple measures. Significant improvements were found in many domains; however, side effects were reported by a substantial proportion of pwCF, with no improvements over time. Female participants reported more side effects than male participants. pwCF should be followed up systematically to assess the frequency of side effects after starting this new modulator.